![]() ![]() Determinants of quality of life in patients with psoriasis: a study from the US population. Quality of life in patients with psoriasis. Psoriasis prevalence among adults in the United States. VH and PH are employees of Novartis, and YZ and FL were employees of Novartis at the time of the study. NG is an employee of Corrona, LLC, and CK was an employee of Corrona, LLC, at the time of the study. ![]() MM is an employee of Corrona, LLC and at the time of the study, was a member of the University of Delaware, Department of Behavioral Health and Nutrition Affiliate Faculty (non-remunerative position). JDG is an employee and shareholder of Corrona, LLC and has been a consultant to Genentech, Janssen, Novartis, Pfizer and Eli Lilly. ML is also a consultant for Allergan, Aqua, Boehringer Ingelheim, Corrona, LEO Pharma, Menlo and Promius. ML is an employee of Mount Sinai and receives research funds from: Abbvie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen/Johnson & Johnson, Leo Pharmaceuticals, Medimmune/Astra Zeneca, Novartis, Pfizer, Sciderm, Valeant and ViDac. Published by BMJ.Ĭompeting interests: BS has served as a consultant for AbbVie, Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Dermira, Galderma, GlaxoSmithKline, Eli Lilly, Janssen, LEO Pharma, Medac, Meiji Seika Pharma, Menlo Therapeutics, Novartis, Ortho Dermatologics/Valeant, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, UCB Pharma, as coscientific director of the Corrona Psoriasis Registry and has received grant support for the University of Connecticut fellowship programme from AbbVie and Janssen. In a real-world setting, more severe psoriasis, assessed by BSA and IGA, was consistently associated with worse PROs.ĭisease severity health-related quality of life patient-reported outcomes psoriasis work productivity. Results were confirmed by multivariable regression analyses. Very severe psoriasis was associated with increased 'work hours missed' and 'work hours affected' (both p<0.05 vs mild psoriasis) Findings were similar by IGA. By BSA score, moderate to very severe psoriasis was associated with poorer outcomes for the 'impairment while working' and 'daily activities impaired' WPAI domains (all p<0.05 vs mild psoriasis). Consistently with more severe psoriasis, symptoms worsened, DLQI scores increased (p<0.05 for each level of BSA and IGA), EQ-VAS decreased (p<0.05 for each level of BSA and IGA) and WPAI scores increased. The mean age was 50.6 years and 47% of patients were female. The association between psoriasis severity and PROs was examined using multivariable regression models. PROs (pain, itch, fatigue Dermatology Life Quality Index EuroQoL Visual Analogue Scale Work Productivity and Activity Impairment ) were compared across BSA and IGA levels using analysis of variance and X 2 tests. Psoriasis severity was assessed by percentage of affected BSA (mild (0%-5%), moderate (>5%-10%), severe (>10%-15%), very severe (>15%)) and IGA scores (clear/almost clear (0-1), mild (2), moderate (3), severe (4)). ![]() This analysis examined the association between psoriasis severity, assessed by body surface area (BSA) and the Investigator's Global Assessment (IGA previously used only in clinical trials), and patient-reported outcomes (PROs) in a real-world setting.Ĭross-sectional analysis within the Corrona Psoriasis Registry, an independent, prospective registry.ġ529 adult patients with psoriasis being treated with biological or non-biological systemic psoriasis treatment by. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |